Chemotherapy or Allogeneic Transplantation in High-Risk Philadelphia Chromosome-Negative Adult Lymphoblastic Leukemia.
暂无分享,去创建一个
J. Esteve | S. Mercadal | M. Tormo | J. Hernández-Rivas | A. Órfão | A. Cladera | J. Ribera | L. Lhermitte | S. Barrena | E. Feliú | J. Serrano | L. Zamora | J. Bergua | P. Montesinos | J. Ribera | M. Morgades | E. Abella | I. Granada | J. Ciudad | M. Amigo | M. Moreno | E. Genescà | P. Martínez-Sánchez | C. Gil | P. Barba | R. Coll | Daniel Martínez-Carballeira | J. González-Campos | R. García-Boyero | A. Novo | F. Vall-llovera | M. Calbacho | I. García-Cadenas | María-José Sánchez-Sánchez | M. Cervera | M. Artola | A. Torrent | M. Penarrubia | A. Bermúdez | N. Alonso | S. Monsalvo | B. de Rueda | A. Garcia-Guiñon | A. Serrano | B. Soria | Josep-Maria Ribera | Jordi Ribera | Carlos Rodríguez | Aurelio López-Martínez | R. Fernández-Martín | Alberto Giménez-Conca | J. Méndez-Sánchez | Matxalen Olivares | Eulàlia Genescà | M. Peñarrubia
[1] S. Mercadal,et al. Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia , 2020, Haematologica.
[2] H. Cavé,et al. IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker? , 2019, Blood.
[3] A. Fielding. Curing Ph+ ALL: assessing the relative contributions of chemotherapy, TKIs, and allogeneic stem cell transplant. , 2019, Hematology. American Society of Hematology. Education Program.
[4] R. Foà,et al. Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial , 2019, Blood.
[5] J. Downing,et al. Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Esteve,et al. Molecular profiling refines minimal residual disease‐based prognostic assessment in adults with Philadelphia chromosome‐negative B‐cell precursor acute lymphoblastic leukemia , 2019, Genes, chromosomes & cancer.
[7] N. Frey. Chimeric antigen receptor T cells for acute lymphoblastic leukemia , 2019, American journal of hematology.
[8] S. Montoto,et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019 , 2019, Bone Marrow Transplantation.
[9] C. Bloomfield,et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. , 2019, Blood.
[10] S. Wetten,et al. A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia , 2019, Haematologica.
[11] C. Pui,et al. Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline. , 2019, Journal of Clinical Oncology.
[12] H. Dombret,et al. Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia , 2019, Hematology.
[13] J. Esteve,et al. Increased survival due to lower toxicity for high‐risk T‐cell acute lymphoblastic leukemia patients in two consecutive pediatric‐inspired PETHEMA trials , 2018, European journal of haematology.
[14] M. Konopleva,et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. , 2018, The Lancet. Haematology.
[15] J. Esteve,et al. Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for , 2018, Bone Marrow Transplantation.
[16] A. Baruchel,et al. Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children? , 2018, Blood.
[17] S. Mercadal,et al. Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia , 2018, Leukemia & lymphoma.
[18] H. Dombret,et al. Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] H. Dombret,et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. , 2018, Blood.
[20] D. Steinemann,et al. IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] M. Konopleva,et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. , 2018, The Lancet. Oncology.
[22] R. Wade,et al. Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] M. Brüggemann,et al. Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. , 2017, Blood advances.
[24] C. Pui,et al. Philadelphia Chromosome–like Acute Lymphoblastic Leukemia , 2017, Clinical lymphoma, myeloma & leukemia.
[25] D. Berry,et al. Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis , 2017, JAMA oncology.
[26] P. Chevallier,et al. Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] W. Klapper,et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia , 2017, The New England journal of medicine.
[28] Quentin Lecrevisse,et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. , 2017, Blood.
[29] A. Vitale,et al. Final Results of Northern Italy Leukemia Group (NILG) Trial 10/07 Combining Pediatric-Type Therapy with Minimal Residual Disease Study and Risk-Oriented Hematopoietic Cell Transplantation in Adult Acute Lymphoblastic Leukemia (ALL) , 2016 .
[30] H. Dombret,et al. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. , 2016, The New England journal of medicine.
[31] M. Liedtke,et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. , 2016, The New England journal of medicine.
[32] G. Salles,et al. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial , 2016, The Lancet.
[33] C. Buske,et al. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] Xuelin Huang,et al. Minimal residual disease assessed by multi‐parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia , 2016, British journal of haematology.
[35] S. Crawford,et al. Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[36] J. Cayuela,et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. , 2015, Blood.
[37] J. Bourhis,et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. , 2015, Blood.
[38] J. Cayuela,et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. , 2014, Blood.
[39] J. Esteve,et al. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] E. Thiel,et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. , 2012, Blood.
[41] R. Pieters,et al. Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008 , 2010, Leukemia.
[42] T. Barbui,et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). , 2009, Blood.